Taysha Gene Therapies, Inc. (TSHA)

Taysha Gene Therapies is a clinical-stage biotech with a pipeline targeting severe monogenic CNS disorders, where successful trial readouts — particularly for its lead TSHA-102 program in Rett syndrome — could represent a transformative value unlock given the high unmet medical need and orphan drug positioning. All 12 covering analysts rate the stock a Buy with zero dissent, reflecting strong conviction in the pipeline's potential and a consensus price target implying over 100% upside from current levels. The primary risk is binary clinical trial outcome dependency, as the company has no revenue, a poor EPS beat history, and must rely on capital markets to fund operations through to potential approval.

• TSHA-102 Phase 1/2 clinical trial data readout for Rett syndrome, which could serve as a major de-risking event and trigger significant re-rating
• Potential FDA Breakthrough Therapy or accelerated approval pathway designations that could shorten time-to-market and validate the clinical program
• Partnership or licensing deal with a larger biopharma that could provide non-dilutive capital and validate pipeline value, reducing cash burn concerns

• Binary clinical risk: a negative or inconclusive Phase 1/2 TSHA-102 readout could erase most of the stock's value given the single-asset dependency
• Cash runway and dilution risk: as a loss-making pre-revenue company with no commercial products, future equity raises could dilute existing shareholders significantly
• Regulatory and manufacturing risk: gene therapy approvals face complex FDA scrutiny around safety (e.g., immune responses to AAV vectors) and CMC requirements that could delay or derail approval timelines

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →